PATHOVAX LLC
Anti-tumor Immune Redirector (AIR) therapeutics that redirect pre-existing vaccine-derived immune responses to target tumor cells
- Sector
- Biotech
- Headquarters
- baltimore, MD
- Founded
- 2014
- Latest Form D
- $2.8M, Aug 2018
- Total capital
- $7M
- Federal grants
- $4.2M
- 7 awards · 2017–2020
- Rank in peer group#152 of 326
- Private capital raised
- $2.8M
- 1 Form D · last Aug 2018
- 98 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantNSF · Phase II · SBIR Phase II: Anti-Tumor Immune Redirectors (AIRs) for cancer treatment$1.4M
- Federal grantHealth and Human S · Phase II · Papillomavirus-like Particles (VLP) as Broad Spectrum Human Papillomavirus (HPV) Vaccines$874K
- Federal grantHealth and Human S · Phase II · Papillomavirus-like Particles (VLP) as Broad Spectrum Human Papillomavirus (HPV) Vaccines$874K
- Federal grantHealth and Human S · Phase I · Broad Spectrum Thermostable Single dose Papillomavirus-like Particles (VLP) for the prevention of all HPV-associated cancers.$300K
- Private capital raisedForm D · SEC · 1st filing$2.8M
- Federal grantNSF · Phase I · SBIR Phase I: Anti-Tumor Immune Redirectors (AIRs) for cancer treatment$225K
- Federal grantHealth and Human S · Phase II · Papillomavirus-like Particles (VLP) as Broad Spectrum Human Papillomavirus (HPV) Vaccines$299K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · Polyionic Papillomavirus-like Particles (VLP) for the Treatment of HPV+ oropharyngeal squamous cell carcinomas (OPCs)$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
11months
from PATHOVAX LLC’s first federal award to its first private round.
- First federal award · Sep 2017
- Health and Human S · $300K
- First Form D · Aug 2018
- $2.8M · 1st Form D
- Awards before first raise
- 3 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#152 · top 47%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Joshua Weiyuan WangResearcherDirector, PromoterLinked by $1.6M in grants as PI
- Weijie Weiyuan PohDirector, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingBivalent Virus-like Particle Compositions And Methods Of UseUSPTOApplication PCTUS2023037041
- PendingBivalent Virus-like Particle Compositions And Methods Of UseUSPTOApplication 63423984
- PendingChimeric Virus-like Particles And Uses Thereof As Antigen-specific Redirectors Of Immune ResponsesUSPTOApplication PCTUS2018038701
Show all 5 patent records
- Bivalent Virus-like Particle Compositions And Methods Of UseApplication PCTUS2023037041Pending
- Bivalent Virus-like Particle Compositions And Methods Of UseApplication 63423984Pending
- Chimeric Virus-like Particles And Uses Thereof As Antigen-specific Redirectors Of Immune ResponsesApplication PCTUS2018038701Pending
- Chimeric Virus-Like Particles and Uses Thereof as Antigen-Specific Redirectors of Immune ResponsesApplication 62676566Pending
- Chimeric Virus-Like Particles and Uses Thereof as Antigen-Specific Redirectors of Immune ResponsesApplication 62524308Pending
Related companies, and why
- LAMASSU PHARMA INC.Similar federal contract value in Biotech · null in contracts
- PHENOTARGET BIOSCIENCES INCSimilar federal contract value in Biotech · null in contracts
- ABILITY DYNAMICS, L.L.C.Similar federal contract value in Biotech · null in contracts
- INTACT THERAPEUTICSSimilar federal contract value in Biotech · null in contracts
- KEVIRX INC.Similar federal contract value in Biotech · null in contracts
- General Folders Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .